| Weight | 1 lbs |
|---|---|
| Dimensions | 9 × 5 × 2 in |
| target | Chlamydia pneumoniae reactive IgM |
| species reactivity | Chlamydia pneumoniae |
| applications | ELISA |
| assay type | Indirect & quantitative |
| available sizes | 96 tests |
Chlamydia pneumoniae IgM ELISA Kit ESR1371M
$334.00
RF-Absorbent Z200 for use with IgM ELISA kits
Did you know that RF Absorbent Z200 is recommended for the removal of IgM rheumatoid factors from serum and plasma samples prior to the detection of pathogen-specific IgM? Consider adding it to your cart for improved signal specificity. For more details, please refer to the IgM ELISA kit protocol.
- Virion/Serion Diagnostic Kit for research use (RUO)
- Chlamydia pneumoniae IgM ELISA Kit
- Suitable for IgM detection
- Ready-to-use
- 96 tests
Chlamydia pneumoniae IgM ELISA Kit ESR1371M
| kit | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assay type Indirect ELISA | ||||||||||||||||||
| Research area Infectious Disease | ||||||||||||||||||
| Sample type Serum, plasma, whole blood | ||||||||||||||||||
| Notes Pretreatment of samples with RF-Absorbent (Z200) is recommended for use with IgM ELISA kits to eliminate presence of sample rheumatoid factors and possible false negative results. | ||||||||||||||||||
Components
| ||||||||||||||||||
| Storage Store at 2-8°C. | ||||||||||||||||||
| Associated products Chlamydia trachomatis EB + RB Antigen (BA1372VSER) Chlamydia trachomatis MOMP Antigen (BA1372VSR2) Chlamydia trachomatis IgA Control Serum (BC1372A) Chlamydia trachomatis IgG Control Serum (BC1372G) Chlamydia trachomatis IgM Control Serum (BC1372M) Chlamydia trachomatis IgA ELISA Kit (ESR1372A) Chlamydia trachomatis IgG ELISA Kit (ESR1372G) Chlamydia trachomatis IgM ELISA Kit (ESR1372M) Chlamydia IgA ELISA Kit (ESR137A) |
| target relevance |
|---|
| Organism Chlamydia pneumoniae |
| Structure and strains Chlamydia pneumoniae is a species of Chlamydia, an obligate intracellular bacterium that infects humans and is a major cause of pneumonia. It was known as the Taiwan acute respiratory agent (TWAR) from the names of the two original isolates Taiwan (TW-183) and an acute respiratory isolate designated AR-39. Briefly, it was known as Chlamydophila pneumoniae, and that name is used as an alternate in some sources. In some cases, to avoid confusion, both names are given. |
| Disease Chlamydiae are gram-negative, obligat intracellular bacteria. Characteristically, the chlamydial cell wall lacks a peptidoglycan layer. Only the species Chlamydia trachomatis, Chlamydia pneumoniae (also referred to as Chlamydophila pneumoniae) and Chlamydia psittaci (also referred to as Chlamydophila psittaci) are relevant to human disease. Chlamydia pneumoniae is an airborne pathogen spread by inhaled droplets. Infections with C. pneumoniae are often asymptomatic or mild. The spectrum of clinical symptoms comprises pharyngitis, sinusitis, bronchitis, pneumonia and myocarditis or endocarditis. Infection may occasionally lead to chronic disease resulting in immunopathological syndromes such as erythema nodosum, arthralgia, Guillain-Barre Syndrome (GBS), or myalgia. In addition, chronic infections with C. pneumoniae are implicated with the etiology of asthma, COPD, atherosclerosis and cardiovascular disease. Approximately 10% of all cases of pneumonia as well as around 5% of infections of the upper respiratory tract are caused by Chlamydia pneumoniae. Diagnosis |
| Detection and diagnosis Diagnosis of a Chlamydia pneumoniae infection is usually based on serological analysis by detection of specific serum antibodies. In the past, the microimmunofluorescence (MIF) test has been used as a reference method. However, it is increasingly replaced by species-specific ELISA tests, which allow for better standardization and automation. Seroprevalence rates rise rapidly in preschool age and reaches >50% after adolescence. Later on in life, the prevalence of C. pneumoniae increases even further due to frequently reoccurring infections and due to its propensity to lead to chronic disease. Beyond 65 years of age, seroprevalence may reach 70-100%. Seroprevalence rates for IgA are barely lower (approximately 60-70%) than for IgG |
Publications
| pmid | title | authors | citation |
|---|---|---|---|
| We haven't added any publications to our database yet. | |||
| relevant to this product |
|---|
| ESR1371M protocol |
| # | ||
|---|---|---|
| Please enter your product and batch number here to retrieve product datasheet, SDS, and QC information. | ||
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.